A National Patient Safety Alert has been issued warning of an impending shortage of specific medicines for Attention Deficit and Hyperactivity Disorders (ADHD).
The supply disruption of these products is attributed to the combined effect of manufacturing issues and increased global demand. Some ADHD products remain available but at insufficient quantities necessary to meet the insurmountable increases in demand. Current expectations are that supply disruptions may resolve at various dates between October 2023 and February 2024. A Medicines Supply Tool is provided by DHSC & CMU and can be access here. Please note registration is required to access this tool.
ADHD
